Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: A general review

International Immunology

Volumn 29, Issue 7, 2017, Pages 319-325

  Kaifu, Tomonori ^a   Nakamura, Akira ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antibody therapy; Autoimmunity; Cancer; Fc receptor; Polymorphism

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ALLERGIC DISEASE; ALLERGY; ARTICLE; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL OUTCOME; COLORECTAL CANCER; COPY NUMBER VARIATION; DRUG MECHANISM; GENETIC POLYMORPHISM; GENETIC VARIATION; HUMAN; IMMUNOPATHOLOGY; LYMPHOMA; MALIGNANT NEOPLASM; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; ANIMAL; GENETICS; HUMORAL IMMUNITY; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNITY, HUMORAL; IMMUNOTHERAPY; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTORS, FC;

EID: 85031920045     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxx041     Document Type: Article

References (78)

1. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2:580.
2. Pincetic, A., Bournazos, S., DiLillo, D. J. et al. 2014. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15:707.
3. Nimmerjahn, F., Gordan, S. and Lux, A. 2015. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 36:325.
4. White, A. L., Beers, S. A. and Cragg, M. S. 2014. FcγRIIB as a key determinant of agonistic antibody efficacy. Curr. Top. Microbiol. Immunol. 382:355.
5. Hargreaves, C. E., Rose-Zerilli, M. J., Machado, L. R. et al. 2015. Fcγ receptors: genetic variation, function, and disease. Immunol. Rev. 268:6.
6. Gillis, C., Gouel-Chéron, A., Jönsson, F. and Bruhns, P. 2014. Contribution of human FcγRs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol. 5:254.
7. Li, X., Gibson, A. W. and Kimberly, R. P. 2014. Human FcR polymorphism and disease. Curr. Top. Microbiol. Immunol. 382:275.
8. Zhou, X. J., Lv, J. C., Bu, D. F. et al. 2010. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int. Immunol. 22:45.
9. Fanciulli, M., Norsworthy, P. J., Petretto, E. et al. 2007. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39:721.
10. Bruhns, P., Iannascoli, B., England, P. et al. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716.
11. Sanders, L. A., Feldman, R. G., Voorhorst-Ogink, M. M. et al. 1995. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun. 63:73.
12. van der Pol, W. L., van den Berg, L. H., Scheepers, R. H. et al. 2000. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology 54:1661.
13. Tsang-A-Sjoe, M. W., Nagelkerke, S. Q., Bultink, I. E. et al. 2016. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford) 55:939.
14. Qiao, J., Al-Tamimi, M., Baker, R. I., Andrews, R. K. and Gardiner, E. E. 2015. The platelet Fc receptor, FcγRIIa. Immunol. Rev. 268:241.
15. Tanaka, Y., Suzuki, Y., Tsuge, T. et al. 2005. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy. Nephrol. Dial. Transplant. 20:2439.
16. Onouchi, Y., Ozaki, K., Burns, J. C. et al.; Japan Kawasaki Disease Genome Consortium; US Kawasaki Disease Genetics Consortium. 2012. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat. Genet. 44:517.
17. Asano, K., Matsushita, T., Umeno, J. et al. 2009. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat. Genet. 41:1325.
18. Espéli, M., Smith, K. G. and Clatworthy, M. R. 2016. FcγRIIB and autoimmunity. Immunol. Rev. 269:194.
19. Floto, R. A., Clatworthy, M. R., Heilbronn, K. R. et al. 2005. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11:1056.
20. Kyogoku, C., Dijstelbloem, H. M., Tsuchiya, N. et al. 2002. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46:1242.
21. van der Heijden, J., Breunis, W. B., Geissler, J., de Boer, M., van den Berg, T. K. and Kuijpers, T. W. 2012. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J. Immunol. 188:1318.
22. Tacke, C. E., Breunis, W. B., Hoang, L. T. et al. 2013. Fc-gamma receptor genetic variation in Kawasaki disease. Arthritis Rheum. 65(Suppl. 10):178.
23. Breunis, W. B., van Mirre, E., Bruin, M. et al. 2008. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111:1029.
24. Li, X., Wu, J., Ptacek, T. et al. 2013. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci. Transl. Med. 5:216ra175.
25. Koene, H. R., Kleijer, M., Swaak, A. J. et al. 1998. The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum. 41:1813.
26. Morgan, A. W., Keyte, V. H., Babbage, S. J. et al. 2003. FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study. Rheumatology (Oxford) 42:528.
27. Moroi, R., Endo, K., Kinouchi, Y. et al. 2013. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 65:265.
28. Aksu, K., Kitapcioglu, G., Keser, G. et al. 2008. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications? Clin. Exp. Rheumatol. 26(4 Suppl. 50):S77.
29. van Sorge, N. M., van der Pol, W. L., Jansen, M. D. et al. 2005. Severity of Guillain-Barré syndrome is associated with Fc gamma receptor III polymorphisms. J. Neuroimmunol. 162:157.
30. Lee, Y. H., Ji, J. D. and Song, G. G. 2008. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. J. Rheumatol. 35:2129.
31. Bournazos, S., Bournazou, I., Murchison, J. T. et al. 2010. Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. Lung 188:475.
32. Kelley, J. M., Monach, P. A., Ji, C. et al. 2011. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc. Natl Acad. Sci. USA 108:20736.
33. Rahbari, R., Zuccherato, L. W., Tischler, G. et al. 2017. Understanding the genomic structure of copy-number variation of the low-affinity Fcγ receptor region allows confirmation of the association of FCGR3B deletion with rheumatoid arthritis. Hum. Mutat. 38:390.
34. Scott, A. M., Wolchok, J. D. and Old, L. J. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12:278.
35. Yu, X. and Lazarus, A. H. 2016. Targeting FcγRs to treat antibodydependent autoimmunity. Autoimmun. Rev. 15:510.
36. Maloney, D. G., Grillo-López, A. J., White, C. A. et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188.
37. Cartron, G., Dacheux, L., Salles, G. et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754.
38. Liu, D., Tian, Y., Sun, D., Sun, H., Jin, Y. and Dong, M. 2016. The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Ann. Hematol. 95:1483.
39. Burkhardt, B., Yavuz, D., Zimmermann, M. et al. 2016. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Ann. Hematol. 95:1503.
40. Ghesquières, H., Cartron, G., Seymour, J. F. et al. 2012. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120:2650.
41. Kenkre, V. P., Hong, F., Cerhan, J. R. et al. 2016. Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma. Clin. Cancer Res. 22:821.
42. Cartron, G., Houot, R. and Kohrt, H. E. 2016. Scientific significance of clinically insignificant FcγRIIIa-V158F polymorphism. Clin. Cancer Res. 22:787.
43. Vaughan, A. T., Iriyama, C., Beers, S. A. et al. 2014. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 123:669.
44. Gabellier, L. and Cartron, G. 2016. Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. Ther. Adv. Hematol. 7:85.
45. Tempescul, A., Bagacean, C., Riou, C. et al. 2016. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. Eur. J. Haematol. 96:229.
46. Wing, M. G., Moreau, T., Greenwood, J. et al. 1996. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98:2819.
47. Nückel, H., Frey, U. H., Röth, A., Dührsen, U. and Siffert, W. 2005. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur. J. Pharmacol. 514:217.
48. Osterborg, A., Karlsson, C., Lundin, J., Kimby, E. and Mellstedt, H. 2006. Strategies in the management of alemtuzumab-related side effects. Semin. Oncol. 33(2 Suppl. 5):S29.
49. Spector, N. L. and Blackwell, K. L. 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27:5838.
50. zum Büschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C. and Bernhard, H. 2002. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62:2244.
51. Kono, K., Sato, E., Naganuma, H. et al. 2004. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin. Cancer Res. 10:2538.
52. Shimizu, C., Mogushi, K., Morioka, M. S. et al. 2016. Fc-gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. Breast Cancer 23:624.
53. Roca, L., Diéras, V., Roché, H. et al. 2013. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res. Treat. 139:789.
54. Arteaga, C. L. and Engelman, J. A. 2014. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282.
55. Trotta, A. M., Ottaiano, A., Romano, C. et al. 2016. Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy. Cancer Immunol. Res. 4:366.
56. Liu, G., Tu, D., Lewis, M. et al. 2016. Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clin. Cancer Res. 22:2435.
57. Lenz, H. J. 2007. Cetuximab in the management of colorectal cancer. Biologics 1:77.
58. Fang, H. and Declerck, Y. A. 2013. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 73:4965.
59. Meyer, T., Robles-Carrillo, L., Robson, T. et al. 2009. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J. Thromb. Haemost. 7:171.
60. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252.
61. Sharma, P. and Allison, J. P. 2015. The future of immune checkpoint therapy. Science 348:56.
62. George, K. and Atkins, P. M. 2015. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 27:39.
63. Blank, C. U. and Enk, A. 2015. Therapeutic use of anti-CTLA-4 antibodies. Int. Immunol. 27:3.
64. Boyerinas, B., Jochems, C., Fantini, M. et al. 2015. Antibodydependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3:1148.
65. Romano, E., Kusio-Kobialka, M., Foukas, P. G. et al. 2015. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112:6140.
66. Horiuchi, T., Mitoma, H., Harashima, S., Tsukamoto, H. and Shimoda, T. 2010. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49:1215.
67. Mitoma, H., Horiuchi, T., Hatta, N. et al. 2005. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128:376.
68. Ueda, N., Tsukamoto, H., Mitoma, H. et al. 2013. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor a. Inflamm. Bowel Dis. 19:1224.
69. Avila-Pedretti, G., Tornero, J., Fernández-Nebro, A. et al. 2015. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS ONE 10:e0122088.
70. Tutuncu, Z., Kavanaugh, A., Zvaifler, N., Corr, M., Deutsch, R. and Boyle, D. 2005. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 52:2693.
71. Kang, S., Tanaka, T. and Kishimoto, T. 2015. Therapeutic uses of anti-interleukin-6 receptor antibody. Int. Immunol. 27:21.
72. Navinés-Ferrer, A., Serrano-Candelas, E., Molina-Molina, G. J. and Martín, M. 2016. IgE-related chronic diseases and anti-IgEbased treatments. J. Immunol. Res. 2016:8163803.
73. Carcao, M. D., Blanchette, V. S., Wakefield, C. D. et al. 2003. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br. J. Haematol. 120:135.
74. Atsumi, T., Caliz, R., Amengual, O., Khamashta, M. A. and Hughes, G. R. 1998. Fcgamma receptor IIA H/R131 polymorphism in patients with antiphospholipid antibodies. Thromb. Haemost. 79:924.
75. Wu, J., Lin, R., Huang, J. et al. 2014. Functional Fcgamma receptor polymorphisms are associated with human allergy. PLoS ONE 9:e89196.
76. Wu, J., Li, Y., Guan, W., Viken, K., Perlman, D. M. and Bhargava, M. 2016. FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis. Hum. Genet. 135:715.
77. Bournazos, S., Bournazou, I., Murchison, J. T. et al. 2011. Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis. Respiration 81:142.
78. Makowsky, R., Wiener, H. W., Ptacek, T. S. et al. 2013. FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response. Pharmacogenet. Genomics 23:455.